Orexin A — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Orexin A

Also known as: Hypocretin-1, OXA, Orexin-A, HCRT1, Prepro-orexin-derived peptide A

Hypothalamic neuropeptide / excitatory peptide

Research chemicalLast updated: October 19, 2026Based on 44 peer-reviewed studies

What it is

Orexin A is a wakefulness-promoting brain peptide studied as a biomarker for narcolepsy and neurodegenerative diseases, and for its potential role in regulating sleep, appetite, and metabolism. Researchers are investigating it as a diagnostic tool and therapeutic target. Not FDA-approved as a therapeutic; drugs that block its receptor are FDA-approved for insomnia.

The scientific side

Orexin A is an excitatory neuropeptide produced primarily in the lateral hypothalamus. It acts on two G-protein-coupled receptors, OX1R and OX2R, which are expressed in the central nervous system and various peripheral tissues including the gastrointestinal tract, kidneys, adrenal glands, pancreas, and placenta. Through OX1R and OX2R signaling, Orexin A participates in the regulation of sleep-wake cycles, arousal, feeding behavior, energy homeostasis, autonomic (sympathetic) tone, reward-seeking, stress responses, and pain modulation. It modulates downstream intracellular pathways including mTOR/p70S6K1, MAPK/ERK, NF-κB, JAK2/STAT3, and PI3K/AKT/mTOR. In peripheral tissues, it exerts anti-inflammatory effects by reducing pro-inflammatory cytokine production and inhibiting NF-κB activation. Its roles in gut-brain signaling, neurodegeneration, and immune modulation are areas of active investigation.

Class: Hypothalamic neuropeptide / excitatory peptide

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification